News and Press Releases
Bionova Scientific Licenses ATUM’s Proprietary Transposon-Based Gene Delivery Technology to Accelerate & De-Risk Cell Line Development
7 May 2025 -- California, US and Düsseldorf, Germany -- Bionova Scientific, an Asahi Kasei boutique commercial-scale biologics contract development and manufacturing organization (CDMO), today announced it has licensed ATUM’s...
Category: Biotechnology, Drug Discovery, Manufacturing and Packing, Pharmaceutical
Posted: May 7, 2025
Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges
Along with PCI’s own robust infrastructure expansions, acquisition furthers CDMO’s recent growth in sterile fill-finish, advanced drug delivery systems like prefilled syringes and cartridges, and biologics – including high potent assets for antibody-drug...
Category: Manufacturing and Packing, Pharmaceutical
Posted: May 1, 2025
PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea
Acquisition creates a world-class large-scale manufacturing hub in San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high potent formulations such as ADCs, complementing existing global sterile...
Category: Logistics, Manufacturing and Packing, Pharmaceutical
Posted: April 24, 2025
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
4 March 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
25 February 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: February 25, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent with Potential as a Next Generation Checkpoint Inhibitor
11 February 2025 -- London, UK -- Ellipses Pharma Limited, a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced...
Category: BioManufacturing, Drug Discovery, Other, Pharmaceutical
Posted: February 11, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded
February 04, 2025 – Berlin, Germany – Biotech Newswire / -- ProBioGen has launched its new, redesigned website to provide biotech and biopharma professionals with clear access to its expanded...
Category: Biotechnology
Posted: February 5, 2025
Rentschler Biopharma announces strategic realignment of its global business operations
30 January 2025 – Laupheim, Germany – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations...
Category: BioManufacturing
Posted: January 30, 2025
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
23 January 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 23, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
17 December 2024 -- New York, US -- Tiziana Life Sciences, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: December 17, 2024
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
LYT-200 is generally safe and well-tolerated as a single agent as well as in combination with standard-of-care venetoclax and hypomethylating agents LYT-200 demonstrates clinical benefit as a single agent, with...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: December 9, 2024
Recipharm’s full range Oral Solid Dosage (OSD) capabilities meet growing industry demands
Full range OSD development and manufacturing capabilities from orphan drugs to blockbusters High potency manufacturing capabilities expansion Introduction of ReciPredict platform to accelerate product development and de-risk tech transfer API...
Category: Manufacturing and Packing
Posted: November 19, 2024
Bespak and Orbia Fluor & Energy Materials unite to accelerate transition to climate-friendly inhalers
Collaboration aims to speed the commercialisation of low global warming potential pMDIs utilising Orbia Fluor & Energy Materials’ Zephex® 152a propellant at Bespak’s Holmes Chapel site 6 November 2024 –...
Category: Drug Delivery, Manufacturing and Packing
Posted: November 6, 2024
53Biologics Awarded Best Company in Biotechnology Innovation at Farmaforum
This award acknowledges the company’s groundbreaking work in microbial expression systems and its ongoing commitment to delivering cutting-edge biotechnological solutions for the global market. 53Biologics, a Contract Development and Manufacturing...
Category: Biotechnology
Posted: October 30, 2024
PCI Pharma Services Wins Supply Chain Excellence Award for Groundbreaking Digital Platform to Manage Clinical Trials and Commercial Lifespans
Leading CDMO’s pci | bridge enhances supply chain visibility and reduces time spent on manual activities such as forecasting, inventory management, reporting, supplier management and document sharing. 30 October 2024...
Category: Biotechnology, Clinical Trials, Drug Discovery, Logistics
Posted: October 30, 2024
